Skip to content
Environment, Medical Health Aged Care

New CDU studies finds two native Australian plants have healing properties

Charles Darwin University 2 mins read

Two plants native to Northern Australia could have significant medicinal potential in the prevention and treatment of diseases, according to two studies by a Charles Darwin University (CDU) PhD candidate.

Lead author and CDU Faculty of Faculty of Science and Technology candidate Elnaz Saki explored the potential of Calophyllum inophyllum seed oil (CSO) and Tinospora smilacina leaves water extract (TSWE) as alternative sources of medicine in two separate studies.

In the first study Dr Saki explored the wound healing potential of CSO after turning it into a nanoemulsion, a mixture of liquids with a nano-sized droplet of oil. The second paper studied the impact of adding TSWE to the CSO nanoemulsion.

“The study has shown that CSO and TSWE contain bioactive compounds such as flavonoids and fatty acids, which have potent wound healing, antimicrobial, and antioxidant effects,” Dr Saki said.

“Both nanoemulsions demonstrated an improvement or equivalent activity for biomedical applications such as wound healing, antimicrobial, and antioxidant effects.”

Dr Saki’s extensive interest in the diversity of plant species and their unique chemical compounds inspired her to pursue medical biotechnology,nanobiotechnology and nanomedicine.

She chose to work with C. inophyllum, also known as Alexandrian laurel, and T. smilacina because of their historical use in traditional medicine and bioactive compounds. CSO has been used to treat skin diseases, wounds and pain while T. smilacina, commonly called snake vine, has long been used by First Nations people to treat snake bites, headaches, rheumatoid arthritis and other inflammatory disorders.

“These plants represent a rich source of bioactive compounds that have not been fully explored regarding their potential therapeutic applications,” Dr Saki said.

“With the increasing demand for sustainable and eco-friendly solutions in the pharmaceutical industry, I recognised an opportunity to contribute to this field by investigating the bioactive properties of plant extracts.”

Dr Saki, who recently graduated with a PhD in Nanobiotechnology, hopes to continue her research and explore how these bioactive compounds work in vitro and in vivo.  

“I am also interested in exploring the potential of these compounds to be included in novel therapies for various diseases, including anti-cancer, anti-inflammation, multidrug-resistant and infectious diseases,” she said.

“I am interested in partnerships with pharmaceutical, bioceutical and cosmetic companies interested in developing and synthesising new nanomedicine and therapies.”

The first study, ‘Optimisation of Calophyllum inophyllum seed oil nanoemulsion as a potential wound healing agent’ was published in the journal of BMC Complementary Medicine and Therapies.

The second study, ‘Formulation and Biomedical Activity of Oil-in-Water Nanoemulsion Combining Tinospora smilacina Water Extract and Calophyllum inophyllum Seeds Oil’ was published in the journal of Clinical, Cosmetic and Investigational Dermatology.


Contact details:

Raphaella Saroukos she/her
Communications Officer
Marketing, Media & Communications
T: +61 8 8946 6721
E: [email protected]
W: cdu.edu.au

Media

More from this category

  • Finance Investment, Medical Health Aged Care
  • 17/03/2026
  • 10:25
Jane Morgan Management

NeuroScientific Biopharmaceuticals (ASX:NSB) Advances StemSmart(TM) Manufacturing Scale-Up as Phase 2 Crohn’s Disease Trial Preparations Progress

Perth, Australia – 17 March 2026 | NeuroScientific Biopharmaceuticals Limited (ASX:NSB) has reached an important development milestone with the commencement of the first technology transfer manufacturing run of its patented StemSmart™ mesenchymal stem cell (MSC) process at leading Australian cell therapy manufacturer Q-Gen Cell Therapeutics. The initiation of the manufacturing run represents a key step in the transfer of the StemSmart™ manufacturing process to a large-scale clinical contract manufacturer that is then capable of providing adequate supply for Phase 2 clinical trials and future commercialisation. Q-Gen Cell Therapeutics, located within the QIMR Berghofer Medical Research Institute in Brisbane, is one…

  • Contains:
  • Environment, Finance Investment
  • 17/03/2026
  • 10:21
HESTA

HESTA launches search for Australia’s early childhood education champions

17 March 2026 The search for Australia’s most outstanding early childhood educators is underway with nominations opening today for the 2026 HESTA Early Childhood…

  • Contains:
  • Medical Health Aged Care
  • 17/03/2026
  • 09:58
Dementia Australia

New support for Australians impacted by CTE

Dementia Australia is proud to announce it has partnered with ConneCTErs Australia to expand the support available for people living with suspected or probable chronic traumatic encephalopathy (CTE) and their carers. As part of the federal government’s $12.4 million CTE Support and Prevention Program, Dementia Australia and ConneCTErs Australia will run a pilot program of support group sessions for people affected by CTE in 11 sites across Australia, including all major cities and select regional locations, as well as online. Dementia Australia CEO Professor Tanya Buchanan said Dementia Australia is excited to be working withConneCTErs Australia to deliver a program…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.